Abstract 833P
Background
In this study, we summarize the chemokines that are involved in malignant HTLV-1 associated disease, adult T cell leukemia/lymphoma (ATLL) progression. The interaction of virus and host were evaluated in chemokine level.
Methods
The expression of CCR6, CXCR-3, the HTLV-1 proviral load (PVL), HTLV-1-Tax, and HBZ were assessed in 12 asymptomatic HTLV-1carriers (ACs), 12 healthy controls (HCs) and 12 ATLL patients. We applied quantitative real-time PCR (qRT-PCR) and TaqMan method.
Results
As per results, the level of CXCR3 gene expression in ATLL patients compared to HTLV-1 virus carriers and healthy people showed a significant difference (P=0.00 and P=0.008). Also, the mean expression of CCR6 genes in ATLL patients compared to HTLV-1 virus carriers had a significant difference of P=0.04, but in the ATLL group there was no significant difference compare to the healthy group.
Conclusions
Our study results illustrate that the expression of chemokine receptors is directly related to the course and stages of the disease as well as the prognosis of the disease. In carriers, compared to healthy individuals, we still have a higher level of expression of chemokine. In addition with the progression of the conflict and the progression to malignancy and involvement of T lymphocytes (the producer of these chemokines) as shown in our study, we can conclude that with decreased levels of these chemokine receptors can lead to malignancy with a poor prognosis. Our findings confirms previous studies that Tax protein may not be expressed in ATLL patients. Additionally an oncoprotein may involve in inducing malignancy, but in the absence of Tax, HTLV-1-HBZ protein implicated in the maintenance of mechanism of the virus to escape from the host cell immune system. We also found an increase in virus load as HTLV-1 carriers move toward. So these chemokines could be suggested as influential targets for the prognosis and proper therapy of ATLL.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1000P - Real-world clinical outcomes of cabozantinib (cabo) as a second-line (2L) treatment for advanced hepatocellular carcinoma (aHCC)
Presenter: Daniel Ahn
Session: Poster session 18
1001P - Patients’ prioritization of treatment goals in hepatocellular carcinoma (HCC): A global qualitative observational study (PERIDOT)
Presenter: Marcus-Alexander Wörns
Session: Poster session 18
1002P - Efficacy and safety of tislelizumab combined with TKIs and FOLFOX4-HAIC in conversion therapy of unresectable hepatocellular carcinoma
Presenter: Kai Tan
Session: Poster session 18
1003P - Efficacy and safety of triple combination therapy with transarterial chemoembolization (TACE), tyrosine kinase inhibitor (TKI), and immune checkpoint inhibitor (ICI) versus dual combination therapy in unresectable hepatocellular carcinoma (uHCC): A systematic review and meta-analysis
Presenter: Omar Maaño
Session: Poster session 18
1004P - Comparative efficacy of systemic sequential regorafenib after sorafenib or lenvatinib treatment failure for advanced hepatocellular carcinoma: A retrospective, multi-center, real-world study
Presenter: Danjun Song
Session: Poster session 18
1005P - Atezolizumab plus bevacizumab combined with transarterial chemoembolization and hepatic arterial infusion chemotherapy for unresectable hepatocellular carcinoma with high tumor burden
Presenter: Jiliang Qiu
Session: Poster session 18
1006P - Associations of online search trends and prescription trends for hepatocellular carcinoma drugs
Presenter: Philipp Berning
Session: Poster session 18
1007P - Network meta-analysis (NMA) of lenvatinib vs key comparators in first-line unresectable hepatocellular carcinoma (uHCC)
Presenter: David Trueman
Session: Poster session 18